Recruiting

Regenecare® Wound Gel with Cetuximab

Sponsor:

Ingalls Memorial Hospital

Code:

NCT00498992

Conditions

Dermatologic Complications

Unspecified Adult Solid Tumor, Protocol Specific

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

collagen/aloe vera/vitamin E/lidocaine topical hydrogel

Study Details

Brief summary:

RATIONALE: Regenecare® wound gel may help relieve pain and itching in patients who develop an acne-like rash while undergoing treatment with cetuximab or another epidermal growth factor receptor inhibitor for cancer.

PURPOSE: This clinical trial is studying how well Regenecare® wound gel works in treating rash in patients receiving cetuximab or another epidermal growth factor receptor inhibitor therapy for cancer.

Conditions

Dermatologic Complications

Unspecified Adult Solid Tumor, Protocol Specific

Study ID

NCT00498992

Start date

Jul, 2006

Status verified date

Jul, 2009

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

DISEASE CHARACTERISTICS:

  • Diagnosis of cancer
  • Starting treatment with cetuximab or other EGFR inhibitor (e.g., erlotinib hydrochloride) on another clinical trial

PATIENT CHARACTERISTICS:

  • Not pregnant or nursing
  • No known history of hypersensitivity to amine-type local anesthetics or to other components of MPM Regenecare® wound gel
  • No other concurrent, serious skin disorders (i.e., scleroderma or psoriasis) that would interfere with assessment of EGFR inhibitor-induced rash

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No other concurrent topical facial creams or lotions

Study Design

Enrollment

20 participants

Anticipated

Primary purpose

Supportive Care

Interventions and Outcome Measures

Interventions

collagen/aloe vera/vitamin E/lidocaine topical hydrogel

Primary outcome measure

  • Efficacy of Regenecare® wound gel, in terms of alleviating pain and itching [ Time Frame: undefined ]

Central Contacts and Locations

Locations

Ingalls Cancer Care Center at Ingalls Memorial Hospital

Recruiting

Harvey, Illinois, United States, 60426

Contacts

Clinical Trials Office - Ingalls Cancer Care Center at Ingalls

708-915-4673

More Information

Sponsor

Ingalls Memorial Hospital

Last update posted

Sep 20, 2013

Last verified

Jul, 2009

Keywords

  • dermatologic complications
  • unspecified adult solid tumor, protocol specific

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Ingalls Memorial Hospital on 2013-09-20.